Is Wells Pharma of Houston legit?

Wells Pharma of Houston is a 503B compounding pharmacy based in Houston, TX. It operates under state board of pharmacy licensure. Note: our records show 2 documented regulatory action(s) — see the Regulatory Actions section below.

Where is Wells Pharma of Houston located?

Wells Pharma of Houston is headquartered in Houston, TX. The pharmacy is licensed to ship to 0 US states.

What does Wells Pharma of Houston produce?

Wells Pharma of Houston produces compounded semaglutide and compounded tirzepatide in addition to other compounded preparations. As a 503B pharmacy, it can batch-produce sterile compounds under FDA cGMP standards.

What is the difference between 503A and 503B?

503A pharmacies prepare compounded medications for individual patients in response to specific prescriptions and are regulated primarily by state boards of pharmacy under USP sterile compounding standards. 503B outsourcing facilities register directly with the FDA, follow current Good Manufacturing Practices (cGMP), and can produce compounded medications in larger batches without patient-specific prescriptions. 503B facilities are subject to FDA inspection.

Compounding Pharmacy · Houston, TX · 503B

Wells Pharma of Houston Review

Wells Pharma of Houston is an FDA-registered 503B outsourcing facility in Houston, Texas that compounded sterile injectables including semaglutide and tirzepatide for clinics and providers during the GLP-1 shortage era. It received an FDA Form 483 in March 2025 and an FDA Warning Letter in November 2025 for sterility-assurance and 503B-compliance deficiencies. It is a separate legal entity from the Wells Pharmacy Network of Ocala, Florida.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

503BFDA Registered 503B

Location: Houston, TX

Website: wellspharma.com

States licensed: 0

5.5

Weight Loss Rankings Score

out of 10

About this pharmacy

Certifications & Compliance

All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards^[4], with finished preparations evaluated against USP <71> sterility testing^[5] and USP <85> bacterial endotoxin testing^[6] as appropriate for the product type.

FDA Registered 503B

Registered directly with the FDA as a 503B outsourcing facility. Subject to FDA inspection and required to follow cGMP standards.

Drugs Produced

Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list^[7].

Yes

Semaglutide

Compounded semaglutide produced

Yes

Tirzepatide

Compounded tirzepatide produced

States Licensed (0)

Regulatory Actions

2025-03-28

FDA Form 483 issued after a March 17-28, 2025 inspection of the Houston 503B outsourcing facility identified serious deficiencies in sterile drug production practices that put patients at risk.

2025-11-07

FDA Warning Letter (FEI 713015) issued to Wells Pharma of Houston, LLC citing drug products that failed to meet section 503B conditions, sterility-assurance deficiencies, and labeling violations on compounded products including semaglutide and tirzepatide.

Weight Loss Rankings Score Breakdown

Accreditation & Compliance6/10

Regulatory Standing5/10

State Coverage0/10

GLP-1 Production10/10

Track Record5/10

Scores are independently researched. See our methodology for details.

High confidence · Last verified 2026-06-04 via manual · How we verify provider data

Frequently Asked Questions

Glossary references

Key terms in this article, linked to their canonical definitions.

Semaglutide · Drugs and brands
Tirzepatide · Drugs and brands
Compounded GLP-1 · Pharmacy and drug forms
503A pharmacy · Pharmacy and drug forms
503B outsourcing facility · Pharmacy and drug forms
PCAB accreditation · Pharmacy and drug forms
Off-label use · Insurance and regulatory
FDA Drug Shortage List · Insurance and regulatory

See Top Semaglutide Providers All Pharmacies

Sources & methodology — as of June 2026

1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
5.USP General Chapter <71> — Sterility Tests— United States Pharmacopeia.
6.USP General Chapter <85> — Bacterial Endotoxins Test— United States Pharmacopeia.
7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.